NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (AMEX: PRW), a bio-pharmaceutical company developing proprietary polysaccharide-based therapeutic compounds in the treatment of cancer and fibrosis, today announced that a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (“FDA”) is scheduled for October to present the clinical development plan for a anti-hypoxia drug to be used in combination with DAVANAT® and 5-FU to treat advanced solid tumors, including head and neck, breast and colorectal cancers. The proposed clinical plan is in direct response to current studies indicating tumors resistance to chemotherapy and radiation are linked to hypoxia.
